{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:22:02Z","timestamp":1790173322600,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FPU21\/06866"],"award-info":[{"award-number":["FPU21\/06866"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum. Genet."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00439-025-02758-6","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:10:04Z","timestamp":1750925404000},"page":"795-807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of delandistrogene moxeparvovec on Duchenne muscular dystrophy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-8752","authenticated-orcid":false,"given":"Carlos","family":"Pascual-Morena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3470-1724","authenticated-orcid":false,"given":"Silvana","family":"Pati\u00f1o-Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-6953","authenticated-orcid":false,"given":"Irene","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-7561","authenticated-orcid":false,"given":"Jaime","family":"Fern\u00e1ndez-Bravo-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4617-616X","authenticated-orcid":false,"given":"Miriam","family":"Garrido-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"2758_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Ginjaar IB, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53:145\u2013151. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103387","journal-title":"J Med Genet"},{"key":"2758_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.nmd.2014.06.224","volume":"24","author":"LN Alfano","year":"2014","unstructured":"Alfano LN, Lowes LP, Berry KM et al (2014) T.P.1: pilot study evaluating motivation on the performance of timed walking in boys with Duchenne muscular dystrophy. Neuromuscul Disord 24:860. https:\/\/doi.org\/10.1016\/j.nmd.2014.06.224","journal-title":"Neuromuscul Disord"},{"key":"2758_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mus.26161","volume":"58","author":"H Arora","year":"2018","unstructured":"Arora H, Willcocks RJ, Lott DJ et al (2018) Longitudinal timed function tests in Duchenne muscular dystrophy: imagingdmd cohort natural history. Muscle Nerve 58:631\u2013638. https:\/\/doi.org\/10.1002\/mus.26161","journal-title":"Muscle Nerve"},{"key":"2758_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.omtm.2023.08.002","volume":"30","author":"D Asher","year":"2023","unstructured":"Asher D, Dai D, Klimchak AC et al (2023) Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene Moxeparvovec. Mol Ther Methods Clin Dev 30:474\u2013483. https:\/\/doi.org\/10.1016\/j.omtm.2023.08.002","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2758_CR5","doi-asserted-by":"publisher","first-page":"e0283669","DOI":"10.1371\/journal.pone.0283669","volume":"18","author":"V Ayyar Gupta","year":"2023","unstructured":"Ayyar Gupta V, Pitchforth JM, Domingos J et al (2023) Determining minimal clinically important differences in the North star ambulatory assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS ONE 18:e0283669. https:\/\/doi.org\/10.1371\/journal.pone.0283669","journal-title":"PLoS ONE"},{"key":"2758_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018a) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and Gastrointestinal and nutritional management. Lancet Neurol 17:251\u2013267. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"key":"2758_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018b) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17:347\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5","journal-title":"Lancet Neurol"},{"key":"2758_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36:395\u2013402. https:\/\/doi.org\/10.1002\/humu.22758","journal-title":"Hum Mutat"},{"key":"2758_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ymthe.2019.01.019","volume":"27","author":"KE Davies","year":"2019","unstructured":"Davies KE, Guiraud S (2019) Micro-dystrophin genes bring hope of an effective therapy for Duchenne muscular dystrophy. Mol Ther 27:486\u2013488. https:\/\/doi.org\/10.1016\/j.ymthe.2019.01.019","journal-title":"Mol Ther"},{"key":"2758_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"2758_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2024.11.005","volume":"163","author":"R Duvuru","year":"2025","unstructured":"Duvuru R, Neumann S, Beemarajan E et al (2025) Acute liver injury following delandistrogene Moxeparvovec gene therapy requiring intravenous Immunoglobulin. Pediatr Neurol 163:1\u20133. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.11.005","journal-title":"Pediatr Neurol"},{"key":"2758_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"2758_CR13","doi-asserted-by":"publisher","first-page":"1107474","DOI":"10.3389\/fneur.2023.1107474","volume":"14","author":"RH Elhalag","year":"2023","unstructured":"Elhalag RH, Motawea KR, Talat NE et al (2023) Efficacy of Vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis. Front Neurol 14:1107474","journal-title":"Front Neurol"},{"key":"2758_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-u","volume":"1","author":"AE Emery","year":"1991","unstructured":"Emery AE (1991) Population frequencies of inherited neuromuscular diseases\u2013a world survey. Neuromuscul Disord 1:19\u201329. https:\/\/doi.org\/10.1016\/0960-8966(91)90039-u","journal-title":"Neuromuscul Disord"},{"key":"2758_CR15","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ (2022) Immunogenicity and toxicity of AAV gene therapy. Front Immunol 13:975803. https:\/\/doi.org\/10.3389\/fimmu.2022.975803","journal-title":"Front Immunol"},{"key":"2758_CR16","unstructured":"Food and Drug Administration (2024) Highlights of prescribing information. https:\/\/www.fda.gov\/media\/169679\/download. Accessed 2 Mar 2025"},{"key":"2758_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00246-021-02797-6","volume":"43","author":"KE Gambetta","year":"2022","unstructured":"Gambetta KE, McCulloch MA, Lal AK et al (2022) Diversity of dystrophin gene mutations and disease progression in a contemporary cohort of Duchenne muscular dystrophy. Pediatr Cardiol 43:855\u2013867. https:\/\/doi.org\/10.1007\/s00246-021-02797-6","journal-title":"Pediatr Cardiol"},{"key":"2758_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"2758_CR19","doi-asserted-by":"publisher","first-page":"23488","DOI":"10.1038\/s41598-024-70783-y","volume":"14","author":"AD Harper","year":"2024","unstructured":"Harper AD, Topaloglu H, Mercuri E et al (2024) Safety and efficacy of Viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy. Sci Rep 14:23488. https:\/\/doi.org\/10.1038\/s41598-024-70783-y","journal-title":"Sci Rep"},{"key":"2758_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"2758_CR20","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions. Cochrane Handbook for Systematic Reviews of Interventions 1\u2013694. https:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"2758_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00108-024-01711-5","volume":"65","author":"S Horn","year":"2024","unstructured":"Horn S, Fehse B (2024) How safe is gene therapy? Second death after Duchenne therapy; [Wie sicher ist die Gentherapie? Zweiter Todesfall nach Therapie der Duchenne-Muskeldystrophie]. Innere Medizin (Germany) 65:617\u2013623. https:\/\/doi.org\/10.1007\/s00108-024-01711-5","journal-title":"Innere Medizin (Germany)"},{"key":"2758_CR23","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Delandistrogene moxeparvovec: first approval. Drugs 83:1323\u20131329. https:\/\/doi.org\/10.1007\/s40265-023-01929-x","journal-title":"Drugs"},{"key":"2758_CR24","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/S0140-6736(25)00717-2","volume":"405","author":"H Jolly","year":"2025","unstructured":"Jolly H, Aartsma-Rus A, Bertini E et al (2025) Gene therapy approval for Duchenne muscular dystrophy: a European perspective. Lancet 405:1572\u20131573","journal-title":"Lancet"},{"key":"2758_CR25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ppul.25261","volume":"56","author":"J Kipke","year":"2021","unstructured":"Kipke J, Birnkrant DJ, Jin JB et al (2021) A systematic review of Pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophy. Pediatr Pulmonol 56:782\u2013795. https:\/\/doi.org\/10.1002\/ppul.25261","journal-title":"Pediatr Pulmonol"},{"key":"2758_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm10040241","volume":"10","author":"KRQ Lim","year":"2020","unstructured":"Lim KRQ, Nguyen Q, Yokota T (2020) Genotype-phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian neuromuscular disease registry. J Pers Med 10:1\u201318. https:\/\/doi.org\/10.3390\/jpm10040241","journal-title":"J Pers Med"},{"key":"2758_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","volume":"7","author":"L-L Ma","year":"2020","unstructured":"Ma L-L, Wang Y-Y, Yang Z-H et al (2020) Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res 7:7. https:\/\/doi.org\/10.1186\/s40779-020-00238-8","journal-title":"Mil Med Res"},{"key":"2758_CR28","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah JK, Korngut L, Dykeman J et al (2014) A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 24:482\u2013491. https:\/\/doi.org\/10.1016\/j.nmd.2014.03.008","journal-title":"Neuromuscul Disord"},{"key":"2758_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00256-004-0825-3","volume":"34","author":"FA Marden","year":"2005","unstructured":"Marden FA, Connolly AM, Siegel MJ, Rubin DA (2005) Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 34:140\u2013148. https:\/\/doi.org\/10.1007\/s00256-004-0825-3","journal-title":"Skeletal Radiol"},{"key":"2758_CR30","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1097\/00002060-199509001-00003","volume":"74","author":"CM McDonald","year":"1995","unstructured":"McDonald CM, Abresch RT, Carter GT et al (1995) Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 74:S70\u201392. https:\/\/doi.org\/10.1097\/00002060-199509001-00003","journal-title":"Am J Phys Med Rehabil"},{"key":"2758_CR34","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K et al (2020) Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: A nonrandomized controlled trial. JAMA Neurol 77:1122\u20131131. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484","journal-title":"JAMA Neurol"},{"key":"2758_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JND-200548","volume":"8","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Khan N, Sha N et al (2021) Comparison of Long-term ambulatory function in patients with Duchenne muscular dystrophy treated with Eteplirsen and matched natural history controls. J Neuromuscul Dis 8:469\u2013479. https:\/\/doi.org\/10.3233\/JND-200548","journal-title":"J Neuromuscul Dis"},{"key":"2758_CR35","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell JR, Shieh PB, McDonald CM et al (2023) Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene Moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol 11:1167762. https:\/\/doi.org\/10.3389\/fcell.2023.1167762","journal-title":"Front Cell Dev Biol"},{"key":"2758_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM et al (2025) AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med 31:332\u2013341. https:\/\/doi.org\/10.1038\/s41591-024-03304-z","journal-title":"Nat Med"},{"key":"2758_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","volume":"153","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Proud C, Zaidman CM et al (2024b) Practical considerations for delandistrogene Moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr Neurol 153:11\u201318. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.01.003","journal-title":"Pediatr Neurol"},{"key":"2758_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Sahenk Z, Lehman KJ et al (2024) Long-term safety and functional outcomes of delandistrogene Moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial. Muscle Nerve 69:93\u201398. https:\/\/doi.org\/10.1002\/mus.27955","journal-title":"Muscle Nerve"},{"key":"2758_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pediatrneurol.2020.08.013","volume":"113","author":"NF Miller","year":"2020","unstructured":"Miller NF, Alfano LN, Iammarino MA et al (2020) Natural history of Steroid-Treated young boys with Duchenne muscular dystrophy using the NSAA, 100m, and timed functional tests. Pediatr Neurol 113:15\u201320. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.08.013","journal-title":"Pediatr Neurol"},{"key":"2758_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2:731\u2013740","journal-title":"Lancet Neurol"},{"key":"2758_CR38","doi-asserted-by":"publisher","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","volume":"14","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Domingos J, Manzur AY et al (2019) Categorising trajectories and individual item changes of the North star ambulatory assessment in patients with Duchenne muscular dystrophy. PLoS ONE 14:e0221097. https:\/\/doi.org\/10.1371\/journal.pone.0221097","journal-title":"PLoS ONE"},{"key":"2758_CR40","doi-asserted-by":"publisher","first-page":"e213604","DOI":"10.1212\/WNL.0000000000213604","volume":"104","author":"M Oskoui","year":"2025","unstructured":"Oskoui M, Caller TA, Parsons JA et al (2025) Delandistrogene Moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy: evidence in focus. Neurology 104:e213604. https:\/\/doi.org\/10.1212\/WNL.0000000000213604","journal-title":"Neurology"},{"key":"2758_CR41","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2758_CR43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51149","volume":"7","author":"C Pascual-Morena","year":"2020","unstructured":"Pascual-Morena C, Cavero-Redondo I, \u00c1lvarez-Bueno C et al (2020) Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review. Ann Clin Transl Neurol 7:1738\u20131752. https:\/\/doi.org\/10.1002\/acn3.51149","journal-title":"Ann Clin Transl Neurol"},{"key":"2758_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15481","author":"C Pascual-Morena","year":"2022","unstructured":"Pascual-Morena C, Cavero-Redondo I, \u00c1lvarez-Bueno C et al (2022a) Global prevalence of intellectual developmental disorder in dystrophinopathies: A systematic review and meta-analysis. Dev Med Child Neurol. https:\/\/doi.org\/10.1111\/dmcn.15481","journal-title":"Dev Med Child Neurol"},{"key":"2758_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2022.05.015","author":"C Pascual-Morena","year":"2022","unstructured":"Pascual-Morena C, Cavero-Redondo I, Reina-Guti\u00e9rrez S et al (2022b) Prevalence of neuropsychiatric disorders in Duchenne and Becker muscular dystrophies: A systematic review and Meta-analysis. Arch Phys Med Rehabil. https:\/\/doi.org\/10.1016\/j.apmr.2022.05.015","journal-title":"Arch Phys Med Rehabil"},{"key":"2758_CR45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40272-024-00655-5","volume":"26","author":"C Pascual-Morena","year":"2024","unstructured":"Pascual-Morena C, Lucer\u00f3n-Lucas-Torres M, Mart\u00ednez-Garc\u00eda I et al (2024) Efficacy and safety of Vamorolone in Duchenne muscular dystrophy: A systematic review. Paediatr Drugs 26:695\u2013707. https:\/\/doi.org\/10.1007\/s40272-024-00655-5","journal-title":"Paediatr Drugs"},{"key":"2758_CR46","unstructured":"Roche (2025) Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD). https:\/\/www.roche.com\/investors\/updates\/inv-update-2025-01-27. Accessed 2 Mar 2025"},{"key":"2758_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1586\/17512433.2014.852065","volume":"7","author":"F Salmon","year":"2014","unstructured":"Salmon F, Grosios K, Petry H (2014) Safety profile of Recombinant adeno-associated viral vectors: focus on alipogene Tiparvovec (Glybera\u00ae). Expert Rev Clin Pharmacol 7:53\u201365. https:\/\/doi.org\/10.1586\/17512433.2014.852065","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2758_CR48","unstructured":"Sarepta Patient Affairs Team (2025) Community Letter: ELEVIDYS Safety Update. Sarepta Therapeutics. https:\/\/www.sarepta.com\/community-letter-elevidys-safety-update. Accessed 25 May 2025"},{"key":"2758_CR49","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"2758_CR50","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, Proud CM, McDonald CM et al (2023) Delandistrogene Moxeparvovec gene therapy in ambulatory patients (Aged\u2009\u2265\u20094 to <\u20098 Years) with Duchenne muscular dystrophy: 1-Year interim results from study SRP-9001-103 (ENDEAVOR). Ann Neurol 94:955\u2013968. https:\/\/doi.org\/10.1002\/ana.26755","journal-title":"Ann Neurol"},{"key":"2758_CR51","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/dmcn.15176","volume":"64","author":"AA Zambon","year":"2022","unstructured":"Zambon AA, Gupta VA, Ridout D et al (2022) Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev Med Child Neurol 64:979\u2013988. https:\/\/doi.org\/10.1111\/dmcn.15176","journal-title":"Dev Med Child Neurol"}],"container-title":["Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00439-025-02758-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:03:04Z","timestamp":1758283384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00439-025-02758-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2758"],"URL":"https:\/\/doi.org\/10.1007\/s00439-025-02758-6","relation":{},"ISSN":["0340-6717","1432-1203"],"issn-type":[{"value":"0340-6717","type":"print"},{"value":"1432-1203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}